Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Marinomed Biotech AG's Debt-to-Equity or its related term are showing as below:
FRA:93Z'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.44 Med: -1.35 Max: 82.71
Current: -1.62
During the past 11 years, the highest Debt-to-Equity Ratio of Marinomed Biotech AG was 82.71. The lowest was -5.44. And the median was -1.35.
FRA:93Z's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs FRA:93Z: -1.62
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Marinomed Biotech AG Debt-to-Equity Related Terms
Marinomed Biotech AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:93Z vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (FRA:93Z) has a Debt-to-Equity of -1.62 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #999999 out of 955 companies in the Biotechnology industry.
Is Marinomed Biotech AG's Debt-to-Equity too high?
Marinomed Biotech AG's current Debt-to-Equity is -1.62. Based on the distribution chart, Marinomed Biotech AG ranks #999999 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #999999 out of 955 companies for Debt-to-Equity. This places Marinomed Biotech AG in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current Debt-to-Equity is -1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (FRA:93Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.44, compared to a current price of €4.24 — trading 77% below its estimated fair value. The current Debt-to-Equity is -1.62. Marinomed Biotech AG's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Marinomed Biotech AG (FRA:93Z), the current Debt-to-Equity is -1.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (FRA:93Z) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €4.24 is trading 77% below its estimated GF Value™ of €18.44.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for FRA:93Z:
Debt-to-Equity: -1.62
GF Value™: €18.44 vs. price of €4.24 (77% below fair value)
No single metric tells the full story. See the FRA:93Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
46GF Score
Get the complete analysis for FRA:93Z
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:93Z has been successfully added to your 
